Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Drug-specific effects of NSAIDs on BP may impact CV risk

Naomi Rodrig
04 Sep 2017
Dr Frank Ruschitzka

Late-breaking data presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain have shown that ibuprofen is associated with greater increase in blood pressure (BP) than celecoxib or naproxen in patients with arthritis, potentially increasing their risk of cardiovascular (CV) events. [Eur Heart J 2017, doi: 10.1093/eurheartj/ehx508]

“Both selective and nonselective NSAIDs are amongst the most widely prescribed drugs worldwide, but are linked with increased BP and CV events,” said lead investigator Dr Frank Ruschitzka from the University Heart Centre in Zurich, Switzerland.  “PRECISION-ABPM [Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen Or Naproxen - Ambulatory Blood Pressure Measurement] was designed to determine the effects of the selective COX-2 inhibitor celecoxib on BP, as compared with the nonselective NSAIDs naproxen and ibuprofen.”

In the randomized, multicentre trial, 444 patients with osteoarthritis or rheumatoid arthritis who had evidence of or were at increased risk of coronary artery disease received celecoxib (100–200 mg BID), ibuprofen (600–800 mg TID) or naproxen (375–500 mg BID) with matching placebos in a 1:1:1 allocation. The primary endpoint was change from baseline in 24-hour ambulatory BP at 4 months. Baseline patient characteristics in terms of age, gender, BP, laboratory tests and co-medication were well matched between the groups.

The change in mean 24-hour systolic BP at 4 months was -0.3 mm Hg for celecoxib, +3.7 mm Hg for ibuprofen and +1.6 mm Hg for naproxen, and these differences manifested regardless of comorbidities such as baseline hypertension or chronic kidney disease. Similar differences between the drugs were observed for diastolic and arterial BP.

“The changes in systolic BP resulted in a significant difference of -3.9 mm Hg between celecoxib and ibuprofen [p=0.0009]. The -1.8 mm Hg difference between celecoxib and naproxen and -2.1 mm Hg difference between naproxen and ibuprofen were not statistically significant,” noted Ruschitzka.

In addition, patients receiving ibuprofen had a 61 percent higher incidence of new-onset hypertension. “The percentage of patients with normal baseline BP who developed hypertension at 4 months was 10.3 percent for celecoxib, 23.2 percent for ibuprofen and 19.0 percent for naproxen,” he reported.

These results support and extend the findings of the original PRECISION trial, which showed a 40 percent lower rate of hospitalization for hypertension with celecoxib vs ibuprofen (p=0.04) but not significantly lower with celecoxib vs naproxen. [N Engl J Med 2016;375:2519-2529]

“The PRECISION trial, which included over 24,000 patients, also indicated a trend towards lower CV and all-cause mortality with celecoxib as compared with ibuprofen or naproxen,” said Ruschitzka.

The finding that ibuprofen is associated with a significant increase in BP, a higher incidence of new-onset hypertension and a higher CV risk suggests that the elevated CV risk with NSAIDs may be partly due to drug-specific increases in BP.

“Increases in systolic BP with different NSAIDs as observed in PRECISION-ABPM should be considered clinically significant, especially for the elderly population with a high prevalence of arthritis and hypertension,” he concluded. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.